US Broker Ratings

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis: Navigating Biotech’s Turbulent Waves with a 52.55% Upside Potential

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a promising name in the biotechnology sector, focusing on therapies for central nervous system disorders. This Boston-based clinical-stage biopharmaceutical company has captured investor..

Geron Corporation (GERN) Stock Analysis: Biotech Pioneer with a Potential Upside of 157.14%

For investors seeking opportunities in the ever-evolving healthcare sector, Geron Corporation (NASDAQ: GERN) presents an intriguing proposition. As a biotechnology company focused on oncology therapeutics, Geron has carved out a..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Unveiling a 19.95% Potential Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biopharmaceutical company, is attracting attention within the biotechnology sector, primarily due to its innovative pipeline and substantial market potential. With a market capitalization..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 64% Potential Upside

In the dynamic world of biotechnology, Trevi Therapeutics, Inc. (NASDAQ: TRVI) is gaining attention from investors with its ambitious clinical trials and promising market outlook. Specializing in treatments for chronic..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 68.79% Potential Upside for Investors

Relay Therapeutics, Inc. (NASDAQ: RLAY), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to drug discovery, particularly in targeted oncology and genetic disease..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Exploring a 42.63% Potential Upside in the Biotech Sector

For investors seeking a promising opportunity in the biotechnology sector, Theravance Biopharma, Inc. (NASDAQ: TBPH) presents a compelling case with a potential upside of 42.63%. With its current stock price..

Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: Potential Upside of 183.41% and Strong Buy Ratings

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is capturing investor attention with a remarkable potential upside of 183.41% as reflected in its current analyst ratings. The company’s focus on innovative therapies for..

Fulgent Genetics (FLGT) Investor Outlook: Exploring 24.65% Potential Upside in the Diagnostics Sector

Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in the healthcare sector, particularly in the diagnostics and research industry, is capturing investor attention with its innovative solutions and notable potential..

CareDx, Inc. (CDNA) Stock Analysis: Exploring a 16.57% Potential Upside in the Healthcare Sector

Investors with an eye on the healthcare sector may find CareDx, Inc. (NASDAQ: CDNA) a compelling prospect. Specializing in diagnostic solutions for transplant patients, CareDx is operating within the ever-evolving..

Tilray Brands, Inc. (TLRY) Stock Analysis: Can 59% Upside Drive Investor Interest?

As the cannabis industry continues to evolve and mature, Tilray Brands, Inc. (NASDAQ: TLRY) stands as a prominent player navigating the complex global landscape of medical and recreational cannabis products...

Kura Oncology, Inc. (KURA) Stock Analysis: Biotech Innovator with a 198% Upside Potential

Kura Oncology, Inc. (NASDAQ: KURA) is making waves within the biotechnology sector, capturing investor attention with its promising pipeline and compelling upside potential. With a market capitalization of $962.41 million,..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: A Biotech with an 80.50% Upside Potential

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is capturing the attention of investors with its significant upside potential in the biotechnology sector. This clinical-stage biopharmaceutical company, based in Newtown Square, Pennsylvania, focuses..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Healthcare Innovator with 139% Potential Upside

Niagen Bioscience, Inc. (NAGE), a burgeoning player in the biotechnology sector, has recently captured the attention of investors with its substantial growth prospects. Based in the United States and trading..

Mind Medicine (MNMD) Stock Analysis: An Investor’s Look at 113% Potential Upside

Mind Medicine (MindMed) Inc. (MNMD) is capturing the attention of investors with its impressive potential upside of 113.45%, according to recent analyst ratings. As a pioneering force in the biotechnology..

Tectonic Therapeutic, Inc. (TECX): Investor Outlook with a Potential 261% Upside

Tectonic Therapeutic, Inc. (NASDAQ: TECX), a promising player in the biotechnology sector, is capturing investor attention with its innovative approach to targeting G protein-coupled receptors (GPCRs). Headquartered in Watertown, Massachusetts,..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Promising 26.73% Upside in the Biotech Sector

Tyra Biosciences, Inc. (NASDAQ: TYRA) is capturing the attention of investors with its potential for significant growth in the healthcare sector. As a clinical-stage biotechnology company, Tyra focuses on developing..

AnaptysBio, Inc. (ANAB) Stock Analysis: 30% Upside Potential with Strong Analyst Support

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company, has been capturing investor attention with its impressive growth metrics and a substantial potential upside. Based in San Diego, California, AnaptysBio specializes..

REGENXBIO Inc. (RGNX) Stock Analysis: Exploring the 110% Potential Upside and Strategic Growth in Gene Therapy

REGENXBIO Inc. (RGNX), a pioneering player in the biotechnology sector, has been capturing attention with its innovative approach to gene therapy. Based in Rockville, Maryland, this clinical-stage company is making..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a Potential 82.5% Upside in Gene Therapy Innovation

For investors looking to capitalize on the burgeoning field of biotechnology, Taysha Gene Therapies, Inc. (TSHA) presents an intriguing opportunity. This Dallas-based company, with a market cap of $1.62 billion,..

uniQure N.V. (QURE) Stock Analysis: Exploring a 120.75% Potential Upside in Gene Therapy Innovation

uniQure N.V. (NASDAQ: QURE), a Dutch biotechnology company, emerges as a noteworthy player in the healthcare sector, focusing on pioneering gene therapies for rare and severe diseases. With a market..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds